Stoke Therapeutics, Inc. is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen ...

Canaccord raised the firm’s price target on Stoke Therapeutics (STOK) to $28 from $24 and keeps a Buy rating on the shares. The firm said they ...

Stoke Therapeutics ( ($STOK) ) has released its Q3 earnings. Here is a breakdown of the information Stoke Therapeutics presented to its investors.

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing ...

Software & Services revenue grows 41% to $305 million Annual recurring revenue grows 41% to $1.3 billion Net loss was $2 million, with non-GAAP net income of $98 million and Adjusted EBITDA of $177 ...

Biogen Inc. and Stoke Therapeutics announced new longer-term data from open-label extension studies of zorevunersen, showing sustained improvements in cognition, behavior, and overall clinical status ...

– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal ...

Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome – ...